These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 15488637)

  • 1. Analysis of familial male breast cancer for germline mutations in CHEK2.
    Sodha N; Wilson C; Bullock SL; Phillimore H; Houlston RS; Eeles RA
    Cancer Lett; 2004 Nov; 215(2):187-9. PubMed ID: 15488637
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CHEK2 1100delC and male breast cancer in the Netherlands.
    Wasielewski M; den Bakker MA; van den Ouweland A; Meijer-van Gelder ME; Portengen H; Klijn JG; Meijers-Heijboer H; Foekens JA; Schutte M
    Breast Cancer Res Treat; 2009 Jul; 116(2):397-400. PubMed ID: 18759107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Germline CHEK2 mutations in Jewish Ashkenazi women at high risk for breast cancer.
    Laitman Y; Kaufman B; Lahad EL; Papa MZ; Friedman E
    Isr Med Assoc J; 2007 Nov; 9(11):791-6. PubMed ID: 18085035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. BRCA1/BRCA2 rearrangements and CHEK2 common mutations are infrequent in Italian male breast cancer cases.
    Falchetti M; Lupi R; Rizzolo P; Ceccarelli K; Zanna I; Calò V; Tommasi S; Masala G; Paradiso A; Gulino A; Giannini G; Russo A; Palli D; Ottini L
    Breast Cancer Res Treat; 2008 Jul; 110(1):161-7. PubMed ID: 17661168
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The CHEK2 c.1100delC germline mutation rarely contributes to breast cancer development in the Czech Republic.
    Kleibl Z; Novotny J; Bezdickova D; Malik R; Kleiblova P; Foretova L; Petruzelka L; Ilencikova D; Cinek P; Pohlreich P
    Breast Cancer Res Treat; 2005 Mar; 90(2):165-7. PubMed ID: 15803363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Homozygosity for a CHEK2*1100delC mutation identified in familial colorectal cancer does not lead to a severe clinical phenotype.
    van Puijenbroek M; van Asperen CJ; van Mil A; Devilee P; van Wezel T; Morreau H
    J Pathol; 2005 Jun; 206(2):198-204. PubMed ID: 15818573
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CHEK2 1100delC is a susceptibility allele for HNPCC-related colorectal cancer.
    Wasielewski M; Vasen H; Wijnen J; Hooning M; Dooijes D; Tops C; Klijn JG; Meijers-Heijboer H; Schutte M
    Clin Cancer Res; 2008 Aug; 14(15):4989-94. PubMed ID: 18676774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CHEK2*1100delC is not an important high-risk gene in families with hereditary prostate cancer in southern Sweden.
    Wagenius M; Borg A; Johansson L; Giwercman A; Bratt O
    Scand J Urol Nephrol; 2006; 40(1):23-5. PubMed ID: 16452051
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The CHEK2*1100delC variant acts as a breast cancer risk modifier in non-BRCA1/BRCA2 multiple-case families.
    Oldenburg RA; Kroeze-Jansema K; Kraan J; Morreau H; Klijn JG; Hoogerbrugge N; Ligtenberg MJ; van Asperen CJ; Vasen HF; Meijers C; Meijers-Heijboer H; de Bock TH; Cornelisse CJ; Devilee P
    Cancer Res; 2003 Dec; 63(23):8153-7. PubMed ID: 14678969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The CHEK2 1100delC variant in Swedish colorectal cancer.
    Djureinovic T; Lindblom A; Dalén J; Dedorson S; Edler D; Hjern F; Holm J; Lenander C; Lindforss U; Lundqvist N; Olivecrona H; Olsson L; Påhlman L; Rutegård J; Smedh K; Törnqvist A; Eiberg H; Bisgaard ML
    Anticancer Res; 2006; 26(6C):4885-8. PubMed ID: 17214356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumour characteristics and prognosis of breast cancer patients carrying the germline CHEK2*1100delC variant.
    de Bock GH; Schutte M; Krol-Warmerdam EM; Seynaeve C; Blom J; Brekelmans CT; Meijers-Heijboer H; van Asperen CJ; Cornelisse CJ; Devilee P; Tollenaar RA; Klijn JG
    J Med Genet; 2004 Oct; 41(10):731-5. PubMed ID: 15466005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of variants in the CHEK2, BRIP1 and PALB2 genes in an Irish breast cancer cohort.
    McInerney NM; Miller N; Rowan A; Colleran G; Barclay E; Curran C; Kerin MJ; Tomlinson IP; Sawyer E
    Breast Cancer Res Treat; 2010 May; 121(1):203-10. PubMed ID: 19763819
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHEK2 1100delC, IVS2+1G>A and I157T mutations are not present in colorectal cancer cases from Turkish population.
    Bayram S; Topaktaş M; Akkız H; Bekar A; Akgöllü E
    Cancer Epidemiol; 2012 Oct; 36(5):453-7. PubMed ID: 22521562
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Breast cancer survival and tumor characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation.
    Schmidt MK; Tollenaar RA; de Kemp SR; Broeks A; Cornelisse CJ; Smit VT; Peterse JL; van Leeuwen FE; Van't Veer LJ
    J Clin Oncol; 2007 Jan; 25(1):64-9. PubMed ID: 17132695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CHEK2*1100delC genotyping for clinical assessment of breast cancer risk: meta-analyses of 26,000 patient cases and 27,000 controls.
    Weischer M; Bojesen SE; Ellervik C; Tybjaerg-Hansen A; Nordestgaard BG
    J Clin Oncol; 2008 Feb; 26(4):542-8. PubMed ID: 18172190
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CHEK2 1100delC is not a risk factor for male breast cancer population.
    Syrjäkoski K; Kuukasjärvi T; Auvinen A; Kallioniemi OP
    Int J Cancer; 2004 Jan; 108(3):475-6. PubMed ID: 14648717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Germline CHEK2*1100delC mutations in breast cancer patients with multiple primary cancers.
    Huang J; Domchek SM; Brose MS; Rebbeck TR; Nathanson KL; Weber BL
    J Med Genet; 2004 Nov; 41(11):e120. PubMed ID: 15520402
    [No Abstract]   [Full Text] [Related]  

  • 18. Low frequency of the CHEK2*1100delC mutation among breast cancer probands from three regions of Poland.
    Kwiatkowska E; Skasko E; Niwinska A; Wojciechowska-Lacka A; Rachtan J; Molong L; Nowakowska D; Konopka B; Janiec-Jankowska A; Paszko Z; Steffen J
    Neoplasma; 2006; 53(4):305-8. PubMed ID: 16830057
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Germline CHEK2 mutations and colorectal cancer risk: different effects of a missense and truncating mutations?
    Cybulski C; Wokołorczyk D; Kładny J; Kurzawski G; Suchy J; Grabowska E; Gronwald J; Huzarski T; Byrski T; Górski B; D Ecedil Bniak T; Narod SA; Lubiński J
    Eur J Hum Genet; 2007 Feb; 15(2):237-41. PubMed ID: 17106448
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Low-penetrance susceptibility to breast cancer due to CHEK2(*)1100delC in noncarriers of BRCA1 or BRCA2 mutations.
    Meijers-Heijboer H; van den Ouweland A; Klijn J; Wasielewski M; de Snoo A; Oldenburg R; Hollestelle A; Houben M; Crepin E; van Veghel-Plandsoen M; Elstrodt F; van Duijn C; Bartels C; Meijers C; Schutte M; McGuffog L; Thompson D; Easton D; Sodha N; Seal S; Barfoot R; Mangion J; Chang-Claude J; Eccles D; Eeles R; Evans DG; Houlston R; Murday V; Narod S; Peretz T; Peto J; Phelan C; Zhang HX; Szabo C; Devilee P; Goldgar D; Futreal PA; Nathanson KL; Weber B; Rahman N; Stratton MR;
    Nat Genet; 2002 May; 31(1):55-9. PubMed ID: 11967536
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.